Publication

Specific delivery of kinase inhibitors in nonmalignant and malignant diseases

van Beuge, M. M., Poelstra, K. & Prakash, J., Jan-2012, In : Expert Opinion on Drug Delivery. 9, 1, p. 59-70 12 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

van Beuge, M. M., Poelstra, K., & Prakash, J. (2012). Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. Expert Opinion on Drug Delivery, 9(1), 59-70. https://doi.org/10.1517/17425247.2012.638625

Author

van Beuge, Marike Marjolijn ; Poelstra, Klaas ; Prakash, Jai. / Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. In: Expert Opinion on Drug Delivery. 2012 ; Vol. 9, No. 1. pp. 59-70.

Harvard

van Beuge, MM, Poelstra, K & Prakash, J 2012, 'Specific delivery of kinase inhibitors in nonmalignant and malignant diseases', Expert Opinion on Drug Delivery, vol. 9, no. 1, pp. 59-70. https://doi.org/10.1517/17425247.2012.638625

Standard

Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. / van Beuge, Marike Marjolijn; Poelstra, Klaas; Prakash, Jai.

In: Expert Opinion on Drug Delivery, Vol. 9, No. 1, 01.2012, p. 59-70.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

van Beuge MM, Poelstra K, Prakash J. Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. Expert Opinion on Drug Delivery. 2012 Jan;9(1):59-70. https://doi.org/10.1517/17425247.2012.638625


BibTeX

@article{b88507510670427bac790d4a1ca3a0e5,
title = "Specific delivery of kinase inhibitors in nonmalignant and malignant diseases",
abstract = "Introduction: Kinase inhibitors have been hailed as a breakthrough in the treatment of cancer. Extensive research is now being devoted to the development of kinase inhibitors as a treatment for many nonmalignant diseases. However, the use of kinase inhibitors in both malignant and nonmalignant diseases is also associated with side effects and the development of resistance. It may be worthwhile to explore whether cell-specific delivery of kinase inhibitors improves therapeutic efficacy and reduces side effects.Areas covered: This review aims to provide an overview of the preclinical studies performed to examine the specific targeting of kinase inhibitors in vitro and in vivo. It gives an introduction to kinase signaling pathways induced during disease, along with the possible problems associated with their inhibition. It also discusses the studies on specific delivery and shows that altering the specificity of kinase inhibitors by targeting methods improves their effectivity and safety.Expert opinion: Compared with the delivery of cytotoxic compounds, the specific delivery of kinase inhibitors has not yet been studied extensively. The studies discussed in this review provide an insight into methods used to target kinase inhibitors to different organs. The targeting of different kinase inhibitors has improved their therapeutic possibilities, but many questions still remain to be studied.",
keywords = "cell-specific, fibrosis, kidney, kinase inhibitor, liver, tumor, HEPATIC STELLATE CELLS, GROWTH-FACTOR-BETA, LIVER FIBROSIS, ROCK INHIBITOR, MANNOSE 6-PHOSPHATE, SIGNALING PATHWAYS, IMATINIB MESYLATE, RENAL FIBROSIS, TUBULOINTERSTITIAL FIBROSIS, INFLAMMATORY DISEASES",
author = "{van Beuge}, {Marike Marjolijn} and Klaas Poelstra and Jai Prakash",
year = "2012",
month = "1",
doi = "10.1517/17425247.2012.638625",
language = "English",
volume = "9",
pages = "59--70",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Taylor and Francis Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Specific delivery of kinase inhibitors in nonmalignant and malignant diseases

AU - van Beuge, Marike Marjolijn

AU - Poelstra, Klaas

AU - Prakash, Jai

PY - 2012/1

Y1 - 2012/1

N2 - Introduction: Kinase inhibitors have been hailed as a breakthrough in the treatment of cancer. Extensive research is now being devoted to the development of kinase inhibitors as a treatment for many nonmalignant diseases. However, the use of kinase inhibitors in both malignant and nonmalignant diseases is also associated with side effects and the development of resistance. It may be worthwhile to explore whether cell-specific delivery of kinase inhibitors improves therapeutic efficacy and reduces side effects.Areas covered: This review aims to provide an overview of the preclinical studies performed to examine the specific targeting of kinase inhibitors in vitro and in vivo. It gives an introduction to kinase signaling pathways induced during disease, along with the possible problems associated with their inhibition. It also discusses the studies on specific delivery and shows that altering the specificity of kinase inhibitors by targeting methods improves their effectivity and safety.Expert opinion: Compared with the delivery of cytotoxic compounds, the specific delivery of kinase inhibitors has not yet been studied extensively. The studies discussed in this review provide an insight into methods used to target kinase inhibitors to different organs. The targeting of different kinase inhibitors has improved their therapeutic possibilities, but many questions still remain to be studied.

AB - Introduction: Kinase inhibitors have been hailed as a breakthrough in the treatment of cancer. Extensive research is now being devoted to the development of kinase inhibitors as a treatment for many nonmalignant diseases. However, the use of kinase inhibitors in both malignant and nonmalignant diseases is also associated with side effects and the development of resistance. It may be worthwhile to explore whether cell-specific delivery of kinase inhibitors improves therapeutic efficacy and reduces side effects.Areas covered: This review aims to provide an overview of the preclinical studies performed to examine the specific targeting of kinase inhibitors in vitro and in vivo. It gives an introduction to kinase signaling pathways induced during disease, along with the possible problems associated with their inhibition. It also discusses the studies on specific delivery and shows that altering the specificity of kinase inhibitors by targeting methods improves their effectivity and safety.Expert opinion: Compared with the delivery of cytotoxic compounds, the specific delivery of kinase inhibitors has not yet been studied extensively. The studies discussed in this review provide an insight into methods used to target kinase inhibitors to different organs. The targeting of different kinase inhibitors has improved their therapeutic possibilities, but many questions still remain to be studied.

KW - cell-specific

KW - fibrosis

KW - kidney

KW - kinase inhibitor

KW - liver

KW - tumor

KW - HEPATIC STELLATE CELLS

KW - GROWTH-FACTOR-BETA

KW - LIVER FIBROSIS

KW - ROCK INHIBITOR

KW - MANNOSE 6-PHOSPHATE

KW - SIGNALING PATHWAYS

KW - IMATINIB MESYLATE

KW - RENAL FIBROSIS

KW - TUBULOINTERSTITIAL FIBROSIS

KW - INFLAMMATORY DISEASES

U2 - 10.1517/17425247.2012.638625

DO - 10.1517/17425247.2012.638625

M3 - Review article

VL - 9

SP - 59

EP - 70

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 1

ER -

ID: 5469766